The Role of Psilocybin in End-of-Life Care: Evidence, Mechanisms, and Guidelines
Mackenzie Unsworth, Mary Lou Galantino, Robert Sandoval
Oncology Rehabilitation in Practice November 1, 2025 DOI: 10.26890/hntj1494 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Key findings | Psilocybin may reduce anxiety and depression in end-of-life care, and clinicians can follow guidelines to assess and integrate its use within legal constraints. |
Abstract
This article aims to provide a brief overview of the evidence and mechanisms for psilocybin use in EOL care. Additionally, this article will provide guidelines for clinicians to assess patient use and integrate psilocybin into their clinical practice with respect to its current legal status.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |